Optimizing blood pressure control through the use of fixed combinations

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 321-325

  Düsing, Rainer ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Blood pressure; Fixed dose combinations; Hypertension

Indexed keywords

ALISKIREN; AMLODIPINE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS VALSARTAN; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; LISINOPRIL; RESERPINE;

ADD ON THERAPY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; COMBINATION CHEMOTHERAPY; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; DRUG EFFICACY; DRUG SENSITIVITY; FIXED DOSE COMBINATION; HUMAN; HYPERTENSION; MONOTHERAPY; OPTIMAL DRUG DOSE; PATIENT ATTITUDE; PATIENT COMPLIANCE; POLYPHARMACY; PRESCRIPTION; REVIEW; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECT; EUROPE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; TABLET; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG COMBINATIONS; EUROPE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; PRACTICE GUIDELINES AS TOPIC; TABLETS; TREATMENT OUTCOME; UNITED STATES;

EID: 77955901459     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s9989     Document Type: Review

References (26)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223.
2. Chobanian AV, Bakris GL, Black HR, et al. National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560-2572.
3. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008;52:818-827.
4. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 204;43:10-17.
5. Chobanian AV. The hypertension paradox - more uncontrolled disease despite improved therapy. N Engl J Med. 2009;361:878-887.
6. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia Is an impediment to achieving the healthy people 2010 blood pressure control goals. Hypertension. 2006;47:345-351.
7. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension. The cycle repeats. Drugs. 2002;62:443-462.
8. Bakris GL. The importance of blood pressure control in the patient with diabetes. Am J Med. 2004;116:30S-38S.
9. Dahlöf B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
10. Jamerson K, Weber MA, Bakris GL, et al. For the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359: 2417-2428.
11. Setaro JF, Black HR. Refractory hypertension. N Engl J Med. 1992;327:543-547.
12. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens. 2007;25:1105-1187.
13. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
14. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-2158.
15. Calhoun DA, Lacourcière Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54:32-39.
16. Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N. Medication compliance: a healthcare problem. Ann Pharmacother. 1993;27(suppl):1-24.
17. Metry J-M. Drug Regimen Compliance: Issues in Clinical Trials and Patient Management. Métry J-M ed. John Wiley and Son Ltd.; 1999.
18. Düsing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive therapy - the role of adverse effects and compliance. Blood Press. 1998;7:313-315.
19. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Int Med. 2005;165:1147-1152.
20. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
21. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States. The Sloane Survey. JAMA. 2002;287:337-344.
22. Bjerrum L, Sogaard J, Hallas J, Kragstrup J. Polypharmacy: correlation with sex, age and drug regimen. A prescription database study. Eur J Clin. Pharmacol. 1998;54:197-202.
23. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5:345-351.
24. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care. 2009;(suppl):2-6.
25. Brixner DI, Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Curr Med Res Opin. 2008;24:597-607.
26. Blonde L, Wogen J, Kreilick C, Seymour AA. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab. 2003;5:424-431.